Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1993 Dec 15;90(24):11683–11687. doi: 10.1073/pnas.90.24.11683

Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain.

P Lanza 1, R Billetta 1, S Antonenko 1, M Zanetti 1
PMCID: PMC48048  PMID: 8265609

Abstract

Using the process of "antibody antigenization," we engineered two antibody molecules carrying in the third complementarity-determining region of the heavy chain variable domain a 7-mer or a 15-mer peptide epitope of the first extracellular domain (D1) of human CD4 receptor--namely, Ser-Phe-Leu-Thr-Lys-Gly-Pro-Ser (SFLTKGPS; positions 42 through 49) and Gly-Ser-Phe-Leu-Thr-Lys-Gly-Pro-Ser-Lys-Leu-Asn-Asp-Arg-Ala (GSFLTKGPSKLNDRA; positions 41 through 55). These amino acid sequences are contained in the consensus binding site for the human immunodeficiency virus (HIV) on CD4 receptor. Both antigenized antibodies (AgAbs) bound recombinant gp120 and were recognized by a prototype monoclonal antibody to CD4 whose binding site is within amino acid residues 41-55. AgAbs were then used as immunogens in rabbits and mice to elicit a humoral response against CD4. Only the AgAb carrying the sequence 41GSFLTKGPSKLN-DRA55 induced a response against CD4. The induced antibodies showed specificity for the amino acid sequence of CD4 engineered in the AgAb molecule, were able to inhibit the formation of syncytia between human CD4+ T cells MOLT-3 and 8E5 (T cells that are constitutively infected with HIV), and stained human CD4+ CEM T cells. Four murine monoclonal antibodies were used to analyze the relationship between syncytia inhibition and CD4 binding at the single antibody level, and indicated that recognition of native CD4 is not an absolute requirement for inhibition of syncytia. This study demonstrates that antigenized antibodies can be used as immunogens to elicit site-specific and biologically active immunity to CD4. The importance of this approach as a general way to induce anti-receptor immunity and as a possible new measure to immunointervention in HIV infection is discussed.

Full text

PDF
11683

Images in this article

11684Fig. 1
on p.11684
11686Fig. 4
on p.11686

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan J. S. Receptor-mediated activation of immunodeficiency viruses in viral fusion. Science. 1991 May 31;252(5010):1322–1323. doi: 10.1126/science.1925547. [DOI] [PubMed] [Google Scholar]
  2. Amadori A., De Silvestro G., Zamarchi R., Veronese M. L., Mazza M. R., Schiavo G., Panozzo M., De Rossi A., Ometto L., Mous J. CD4 epitope masking by gp120/anti-gp120 antibody complexes. A potential mechanism for CD4+ cell function down-regulation in AIDS patients. J Immunol. 1992 May 1;148(9):2709–2716. [PubMed] [Google Scholar]
  3. Berger E. A., Lifson J. D., Eiden L. E. Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like region in membrane fusion. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8082–8086. doi: 10.1073/pnas.88.18.8082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Billetta R., Hollingdale M. R., Zanetti M. Immunogenicity of an engineered internal image antibody. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4713–4717. doi: 10.1073/pnas.88.11.4713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cameron P. U., Freudenthal P. S., Barker J. M., Gezelter S., Inaba K., Steinman R. M. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science. 1992 Jul 17;257(5068):383–387. doi: 10.1126/science.1352913. [DOI] [PubMed] [Google Scholar]
  6. Cammarota G., Scheirle A., Takacs B., Doran D. M., Knorr R., Bannwarth W., Guardiola J., Sinigaglia F. Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. Nature. 1992 Apr 30;356(6372):799–801. doi: 10.1038/356799a0. [DOI] [PubMed] [Google Scholar]
  7. Capon D. J., Chamow S. M., Mordenti J., Marsters S. A., Gregory T., Mitsuya H., Byrn R. A., Lucas C., Wurm F. M., Groopman J. E. Designing CD4 immunoadhesins for AIDS therapy. Nature. 1989 Feb 9;337(6207):525–531. doi: 10.1038/337525a0. [DOI] [PubMed] [Google Scholar]
  8. Clapham P. R., Weber J. N., Whitby D., McIntosh K., Dalgleish A. G., Maddon P. J., Deen K. C., Sweet R. W., Weiss R. A. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature. 1989 Jan 26;337(6205):368–370. doi: 10.1038/337368a0. [DOI] [PubMed] [Google Scholar]
  9. Clayton L. K., Hussey R. E., Steinbrich R., Ramachandran H., Husain Y., Reinherz E. L. Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding. Nature. 1988 Sep 22;335(6188):363–366. doi: 10.1038/335363a0. [DOI] [PubMed] [Google Scholar]
  10. Crowe S. M., Mills J., Kirihara J., Boothman J., Marshall J. A., McGrath M. S. Full-length recombinant CD4 and recombinant gp120 inhibit fusion between HIV infected macrophages and uninfected CD4-expressing T-lymphoblastoid cells. AIDS Res Hum Retroviruses. 1990 Aug;6(8):1031–1037. doi: 10.1089/aid.1990.6.1031. [DOI] [PubMed] [Google Scholar]
  11. Daar E. S., Li X. L., Moudgil T., Ho D. D. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6574–6578. doi: 10.1073/pnas.87.17.6574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Deen K. C., McDougal J. S., Inacker R., Folena-Wasserman G., Arthos J., Rosenberg J., Maddon P. J., Axel R., Sweet R. W. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature. 1988 Jan 7;331(6151):82–84. doi: 10.1038/331082a0. [DOI] [PubMed] [Google Scholar]
  13. Fisher R. A., Bertonis J. M., Meier W., Johnson V. A., Costopoulos D. S., Liu T., Tizard R., Walker B. D., Hirsch M. S., Schooley R. T. HIV infection is blocked in vitro by recombinant soluble CD4. Nature. 1988 Jan 7;331(6151):76–78. doi: 10.1038/331076a0. [DOI] [PubMed] [Google Scholar]
  14. Folks T. M., Powell D., Lightfoote M., Koenig S., Fauci A. S., Benn S., Rabson A., Daugherty D., Gendelman H. E., Hoggan M. D. Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med. 1986 Jul 1;164(1):280–290. doi: 10.1084/jem.164.1.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hart T. K., Kirsh R., Ellens H., Sweet R. W., Lambert D. M., Petteway S. R., Jr, Leary J., Bugelski P. J. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2189–2193. doi: 10.1073/pnas.88.6.2189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hussey R. E., Richardson N. E., Kowalski M., Brown N. R., Chang H. C., Siliciano R. F., Dorfman T., Walker B., Sodroski J., Reinherz E. L. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature. 1988 Jan 7;331(6151):78–81. doi: 10.1038/331078a0. [DOI] [PubMed] [Google Scholar]
  17. Lederman S., Yellin M. J., Cleary A. M., Gulick R., Chess L. Recombinant, truncated CD4 molecule (rT4) binds IgG. J Immunol. 1990 Jan 1;144(1):214–220. [PubMed] [Google Scholar]
  18. Lenert P., Kroon D., Spiegelberg H., Golub E. S., Zanetti M. Human CD4 binds immunoglobulins. Science. 1990 Jun 29;248(4963):1639–1643. doi: 10.1126/science.2363051. [DOI] [PubMed] [Google Scholar]
  19. McClelland A., deBear J., Yost S. C., Meyer A. M., Marlor C. W., Greve J. M. Identification of monoclonal antibody epitopes and critical residues for rhinovirus binding in domain 1 of intercellular adhesion molecule 1. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):7993–7997. doi: 10.1073/pnas.88.18.7993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. McKeating J., Balfe P., Clapham P., Weiss R. A. Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity. J Virol. 1991 Sep;65(9):4777–4785. doi: 10.1128/jvi.65.9.4777-4785.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Michaels J., Price R. W., Rosenblum M. K. Microglia in the giant cell encephalitis of acquired immune deficiency syndrome: proliferation, infection and fusion. Acta Neuropathol. 1988;76(4):373–379. doi: 10.1007/BF00686974. [DOI] [PubMed] [Google Scholar]
  22. Moore J. P., McKeating J. A., Weiss R. A., Sattentau Q. J. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science. 1990 Nov 23;250(4984):1139–1142. doi: 10.1126/science.2251501. [DOI] [PubMed] [Google Scholar]
  23. Pantaleo G., Poli G., Butini L., Fox C., Dayton A. I., Fauci A. S. Dissociation between syncytia formation and HIV spreading. Suppression of syncytia formation does not necessarily reflect inhibition of HIV infection. Eur J Immunol. 1991 Jul;21(7):1771–1774. doi: 10.1002/eji.1830210730. [DOI] [PubMed] [Google Scholar]
  24. Peterson A., Seed B. Genetic analysis of monoclonal antibody and HIV binding sites on the human lymphocyte antigen CD4. Cell. 1988 Jul 1;54(1):65–72. doi: 10.1016/0092-8674(88)90180-8. [DOI] [PubMed] [Google Scholar]
  25. Register R. B., Uncapher C. R., Naylor A. M., Lineberger D. W., Colonno R. J. Human-murine chimeras of ICAM-1 identify amino acid residues critical for rhinovirus and antibody binding. J Virol. 1991 Dec;65(12):6589–6596. doi: 10.1128/jvi.65.12.6589-6596.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ryu S. E., Kwong P. D., Truneh A., Porter T. G., Arthos J., Rosenberg M., Dai X. P., Xuong N. H., Axel R., Sweet R. W. Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature. 1990 Nov 29;348(6300):419–426. doi: 10.1038/348419a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sattentau Q. J., Arthos J., Deen K., Hanna N., Healey D., Beverley P. C., Sweet R., Truneh A. Structural analysis of the human immunodeficiency virus-binding domain of CD4. Epitope mapping with site-directed mutants and anti-idiotypes. J Exp Med. 1989 Oct 1;170(4):1319–1334. doi: 10.1084/jem.170.4.1319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sattentau Q. J., Dalgleish A. G., Weiss R. A., Beverley P. C. Epitopes of the CD4 antigen and HIV infection. Science. 1986 Nov 28;234(4780):1120–1123. doi: 10.1126/science.2430333. [DOI] [PubMed] [Google Scholar]
  29. Schooley R. T., Merigan T. C., Gaut P., Hirsch M. S., Holodniy M., Flynn T., Liu S., Byington R. E., Henochowicz S., Gubish E. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med. 1990 Feb 15;112(4):247–253. doi: 10.7326/0003-4819-112-4-247. [DOI] [PubMed] [Google Scholar]
  30. Selinka H. C., Zibert A., Wimmer E. Poliovirus can enter and infect mammalian cells by way of an intercellular adhesion molecule 1 pathway. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3598–3602. doi: 10.1073/pnas.88.9.3598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Smith D. H., Byrn R. A., Marsters S. A., Gregory T., Groopman J. E., Capon D. J. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science. 1987 Dec 18;238(4834):1704–1707. doi: 10.1126/science.3500514. [DOI] [PubMed] [Google Scholar]
  32. Sodroski J., Goh W. C., Rosen C., Campbell K., Haseltine W. A. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. 1986 Jul 31-Aug 6Nature. 322(6078):470–474. doi: 10.1038/322470a0. [DOI] [PubMed] [Google Scholar]
  33. Sollazzo M., Castiglia D., Billetta R., Tramontano A., Zanetti M. Structural definition by antibody engineering of an idiotypic determinant. Protein Eng. 1990 May;3(6):531–539. doi: 10.1093/protein/3.6.531. [DOI] [PubMed] [Google Scholar]
  34. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Traunecker A., Lüke W., Karjalainen K. Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature. 1988 Jan 7;331(6151):84–86. doi: 10.1038/331084a0. [DOI] [PubMed] [Google Scholar]
  36. Turner S., Tizard R., DeMarinis J., Pepinsky R. B., Zullo J., Schooley R., Fisher R. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1335–1339. doi: 10.1073/pnas.89.4.1335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wang J. H., Yan Y. W., Garrett T. P., Liu J. H., Rodgers D. W., Garlick R. L., Tarr G. E., Husain Y., Reinherz E. L., Harrison S. C. Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature. 1990 Nov 29;348(6300):411–418. doi: 10.1038/348411a0. [DOI] [PubMed] [Google Scholar]
  38. Watanabe M., Boyson J. E., Lord C. I., Letvin N. L. Chimpanzees immunized with recombinant soluble CD4 develop anti-self CD4 antibody responses with anti-human immunodeficiency virus activity. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5103–5107. doi: 10.1073/pnas.89.11.5103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Watanabe M., Chen Z. W., Tsubota H., Lord C. I., Levine C. G., Letvin N. L. Soluble human CD4 elicits an antibody response in rhesus monkeys that inhibits simian immunodeficiency virus replication. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):120–124. doi: 10.1073/pnas.88.1.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Watanabe M., Levine C. G., Shen L., Fisher R. A., Letvin N. L. Immunization of simian immunodeficiency virus-infected rhesus monkeys with soluble human CD4 elicits an antiviral response. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4616–4620. doi: 10.1073/pnas.88.11.4616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Zanetti M. Antigenized antibodies. Nature. 1992 Jan 30;355(6359):476–477. doi: 10.1038/355476a0. [DOI] [PubMed] [Google Scholar]
  42. Zanetti M., Glotz D., Rogers J. Perturbation of the autoimmune network. II. Immunization with isologous idiotype induces auto-anti-idiotypic antibodies and suppresses the autoantibody response elicited by antigen: a serologic and cellular analysis. J Immunol. 1986 Nov 15;137(10):3140–3146. [PubMed] [Google Scholar]
  43. Zanetti M., Rossi F., Lanza P., Filaci G., Lee R. H., Billetta R. Theoretical and practical aspects of antigenized antibodies. Immunol Rev. 1992 Dec;130:125–150. doi: 10.1111/j.1600-065x.1992.tb01524.x. [DOI] [PubMed] [Google Scholar]
  44. Zanetti M., Wilson C. B. Participation of auto-anti-idiotypes in immune complex glomerulonephritis in rabbits. J Immunol. 1983 Dec;131(6):2781–2783. [PubMed] [Google Scholar]
  45. Zibert A., Selinka H. C., Elroy-Stein O., Moss B., Wimmer E. Vaccinia virus-mediated expression and identification of the human poliovirus receptor. Virology. 1991 May;182(1):250–259. doi: 10.1016/0042-6822(91)90668-2. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES